Tiaprofenic acid
Brand names: Surgam
Tiaprofenic acid is a non-steroidal anti-inflammatory drug used for pain and inflammation in rheumatic disease and other musculoskeletal disorders.
ClinCalc Pro is rebuilding its dose data from primary open sources — the manufacturer SmPC (eMC), the WHO Model Formulary and other official references — under clinician review. This drug's structured dose is not yet published here. Confirm all doses against the product SmPC and your local formulary before prescribing.
Clinical monograph
How it works
It inhibits cyclo-oxygenase, reducing prostaglandin synthesis and producing anti-inflammatory and analgesic effects.
Prescribing in practice
- It can cause severe cystitis and urinary symptoms, and should be stopped immediately and not restarted if urinary frequency, pain, urgency or haematuria develops.
- As with all NSAIDs it carries gastrointestinal, cardiovascular and renal risks and should be used at the lowest effective dose for the shortest time.
- It interacts with anticoagulants, other NSAIDs, diuretics, ACE inhibitors and lithium; avoid in patients with active peptic ulceration or significant renal impairment.
Monitoring
Monitor for urinary symptoms, renal function and gastrointestinal tolerability, particularly during prolonged use.
Counselling the patient
- Stop the medicine and tell your doctor at once if you develop bladder symptoms such as needing to pass urine often, pain on passing urine, or blood in the urine.
- Take it with or after food and report indigestion or black stools.
- Avoid combining it with other anti-inflammatory painkillers unless advised.
Evidence & guidelines
The MHRA has highlighted the risk of severe cystitis with tiaprofenic acid, advising prompt discontinuation if urinary symptoms occur.
Reference: MHRA; Drug verified in RxNorm (NLM); confirm dosing against the manufacturer SPC (eMC). Verify against your local formulary and current prescribing references before prescribing. Monograph status: clinician-reviewed (2026-07-04).
Related
Curated clinical cross-links plus same-class fallbacks.
- Cutaneous Lupus Erythematosus · BAD; EULAR
- Osteoporosis / Fragility Fracture · NOGG 2021; NICE NG147; NG224
- Arteritic AION (Giant Cell Arteritis) · RCOphth; BSR
- Osteoarthritis Hip / Knee Management · NICE NG226 (2022)
- Lupus Nephritis · EULAR/ERA-EDTA 2019; KDIGO 2024
- Rheumatoid Arthritis Management · NICE CG79 2018 / EULAR 2022